Patent Expiry

Patent/Exclusivity Expiry: IMCIVREE

Other upcoming events for RYTM

Phase 2 ReadoutPhase 2 Readout: setmelanotide
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of S
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: IMCIVREE — RYTM Patent Expiry | BioSniper